Fecal microbiota-based treatment for recurrent Clostridioides difficile infection

Jens Walter; Fergus Shanahan

doi:10.1016/j.cell.2023.02.034

Fecal microbiota-based treatment for recurrent Clostridioides difficile infection

Jens Walter
, Fergus Shanahan

University College Cork

Research output: Contribution to journal › Comment/Debate

Abstract

Rebyota is a rectally administered fecal microbiota suspension for prevention of recurrence of Clostridioides difficile infection. The mechanism of action of Rebyota probably involves competitive exclusion of C. difficile by donor microbes with reduced toxin production; other factors may include restoration of protective taxa and modulation of the recipient's microbiome by phage, donor microbes, or metabolites.

Original language	English
Pages (from-to)	1087
Number of pages	1
Journal	Cell
Volume	186
Issue number	6
DOIs	https://doi.org/10.1016/j.cell.2023.02.034
Publication status	Published - 16 Mar 2023

Access to Document

10.1016/j.cell.2023.02.034

Cite this

@article{11bf22520a90423ca608b28a0dea96e0,

title = "Fecal microbiota-based treatment for recurrent Clostridioides difficile infection",

abstract = "Rebyota is a rectally administered fecal microbiota suspension for prevention of recurrence of Clostridioides difficile infection. The mechanism of action of Rebyota probably involves competitive exclusion of C. difficile by donor microbes with reduced toxin production; other factors may include restoration of protective taxa and modulation of the recipient's microbiome by phage, donor microbes, or metabolites.",

author = "Jens Walter and Fergus Shanahan",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = mar,

day = "16",

doi = "10.1016/j.cell.2023.02.034",

language = "English",

volume = "186",

pages = "1087",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier B.V.",

number = "6",

}

TY - JOUR

T1 - Fecal microbiota-based treatment for recurrent Clostridioides difficile infection

AU - Walter, Jens

AU - Shanahan, Fergus

PY - 2023/3/16

Y1 - 2023/3/16

N2 - Rebyota is a rectally administered fecal microbiota suspension for prevention of recurrence of Clostridioides difficile infection. The mechanism of action of Rebyota probably involves competitive exclusion of C. difficile by donor microbes with reduced toxin production; other factors may include restoration of protective taxa and modulation of the recipient's microbiome by phage, donor microbes, or metabolites.

AB - Rebyota is a rectally administered fecal microbiota suspension for prevention of recurrence of Clostridioides difficile infection. The mechanism of action of Rebyota probably involves competitive exclusion of C. difficile by donor microbes with reduced toxin production; other factors may include restoration of protective taxa and modulation of the recipient's microbiome by phage, donor microbes, or metabolites.

UR - https://www.scopus.com/pages/publications/85150378437

U2 - 10.1016/j.cell.2023.02.034

DO - 10.1016/j.cell.2023.02.034

M3 - Comment/Debate

C2 - 36931236

AN - SCOPUS:85150378437

SN - 0092-8674

VL - 186

SP - 1087

JO - Cell

JF - Cell

IS - 6

ER -

Fecal microbiota-based treatment for recurrent Clostridioides difficile infection

Abstract

Access to Document

Other files and links

Fingerprint

Cite this